PMID- 25645592
OWN - NLM
STAT- MEDLINE
DCOM- 20151231
LR  - 20191210
IS  - 1399-3062 (Electronic)
IS  - 1398-2273 (Linking)
VI  - 17
IP  - 2
DP  - 2015 Apr
TI  - Infectious complications following allogeneic stem cell transplantation by using 
      anti-thymocyte globulin-based myeloablative conditioning regimens in children 
      with hemoglobinopathies.
PG  - 201-7
LID - 10.1111/tid.12358 [doi]
AB  - BACKGROUND: Anti-thymocyte globulin (ATG) has been used to prevent graft 
      failure/rejection in the setting of allogeneic stem cell transplantation 
      (allo-SCT) for hemoglobinopathies; however, epidemiology data for 
      transplant-related infections in this population are scarce. METHOD: We 
      retrospectively analyzed the epidemiology of bacterial, fungal, viral, and 
      parasitic infections in a cohort of 105 children and adolescents with 
      beta-thalassemia (n = 100) or sickle cell disease (n = 5) who underwent allo-SCT 
      using human leukocyte antigen (HLA)-identical sibling (n = 96) or HLA-compatible 
      unrelated donors (n = 9) in a single institution. All patients received an 
      ATG-based conditioning regimen. RESULTS: The cumulative incidence of 
      cytomegalovirus (CMV) viremia was 45.7% (95% confidence interval [CI] 33-55%), 
      developing at a median of 48 (range 12-142) days without evidence of overt CMV 
      disease. Herpes zoster developed in 8 patients at a median of 12 months post 
      transplant, while 10 patients presented with late onset hemorrhagic cystitis at a 
      median of 35 days post transplant. The cumulative incidence of bacteremia was 
      17.1% (95% CI 10.6-25%), occurring at a median of 74 (range 24-110) days. No 
      patient developed probable or definite invasive fungal infection. Four deaths 
      were recorded; 2 of them were attributed to infections (toxoplasmosis and 
      Pneumocystis jirovecii pneumonia, respectively). CONCLUSION: The rate of 
      infections after allo-SCT, using an ATG-containing preparative regimen, in our 
      population of pediatric patients with hemoglobinopathies is comparable to that 
      reported elsewhere with the use of non-ATG containing regimens.
CI  - (c) 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Goussetis, E
AU  - Goussetis E
AD  - Stem Cell Transplant Unit, Aghia Sophia Children's Hospital, Thivon and 
      Papadiamantopoulou, Athens, Greece.
FAU - Efstathiou, E
AU  - Efstathiou E
FAU - Paisiou, A
AU  - Paisiou A
FAU - Avgerinou, G
AU  - Avgerinou G
FAU - Zisaki, K
AU  - Zisaki K
FAU - Giamouris, V J
AU  - Giamouris VJ
FAU - Peristeri, I
AU  - Peristeri I
FAU - Kitra, V
AU  - Kitra V
FAU - Vessalas, G
AU  - Vessalas G
FAU - Gamaletsou, M N
AU  - Gamaletsou MN
FAU - Sipsas, N V
AU  - Sipsas NV
FAU - Graphakos, S
AU  - Graphakos S
LA  - eng
PT  - Journal Article
DEP - 20150307
PL  - Denmark
TA  - Transpl Infect Dis
JT  - Transplant infectious disease : an official journal of the Transplantation 
      Society
JID - 100883688
RN  - 0 (Antilymphocyte Serum)
RN  - 0 (Immunosuppressive Agents)
RN  - 83HN0GTJ6D (Cyclosporine)
SB  - IM
MH  - Adolescent
MH  - Anemia, Sickle Cell/*therapy
MH  - Antilymphocyte Serum/*adverse effects
MH  - Bacteremia/etiology/immunology
MH  - Child
MH  - Cohort Studies
MH  - Cyclosporine/therapeutic use
MH  - Cystitis/etiology/immunology
MH  - Cytomegalovirus Infections/etiology/immunology
MH  - Female
MH  - Graft vs Host Disease/prevention & control
MH  - Hematopoietic Stem Cell Transplantation/*methods
MH  - Herpes Zoster/etiology/immunology
MH  - Humans
MH  - *Immunocompromised Host
MH  - Immunosuppressive Agents/*adverse effects
MH  - Infections/*etiology/immunology
MH  - Male
MH  - Pneumonia, Pneumocystis/etiology/immunology
MH  - Retrospective Studies
MH  - Toxoplasmosis/etiology/immunology
MH  - Transplantation Conditioning/*adverse effects
MH  - Viremia/etiology/immunology
MH  - beta-Thalassemia/*therapy
OTO - NOTNLM
OT  - ATG
OT  - hemoglobinopathies
OT  - infections
OT  - stem cell transplantation
EDAT- 2015/02/04 06:00
MHDA- 2016/01/01 06:00
CRDT- 2015/02/04 06:00
PHST- 2014/10/01 00:00 [received]
PHST- 2014/12/29 00:00 [revised]
PHST- 2015/01/11 00:00 [accepted]
PHST- 2015/02/04 06:00 [entrez]
PHST- 2015/02/04 06:00 [pubmed]
PHST- 2016/01/01 06:00 [medline]
AID - 10.1111/tid.12358 [doi]
PST - ppublish
SO  - Transpl Infect Dis. 2015 Apr;17(2):201-7. doi: 10.1111/tid.12358. Epub 2015 Mar 
      7.